July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
FDA advisory committee meeting notice listing multiple peptide bulk substances scheduled for discussion.
Source registry
Tracked sources
The source registry keeps citation metadata separate from page copy so claims can be audited and refreshed.
Certain bulk drug substances for use in compounding may present significant safety risks
FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.
Warning Letter: Gram Peptides
FDA warning letter discussing peptide products marketed online and the limits of research-use-only positioning.
Retatrutide for Obesity — A Phase 2 Trial
Phase 2 randomized trial of retatrutide (LY3437943), a triple GLP-1/GIP/glucagon receptor agonist, showing dose-dependent weight loss up to 17.5% at 48 weeks in adults with obesity.
TRIUMPH Phase 3 Trial Program for Retatrutide — ClinicalTrials.gov
ClinicalTrials.gov registry entry for the TRIUMPH Phase 3 trial program evaluating retatrutide for obesity, sponsored by Eli Lilly. Retatrutide is not FDA-approved for any indication.
Retatrutide Masterclass: How To Use It Optimally (Dose, Frequency, Diet, Exercise, & Supplements)
Long-form YouTube video by a medical doctor discussing retatrutide with chapters on monitoring, diet, and exercise. Tracked as a media signal for public claim patterns.
Dr. Explains Why Retatrutide is KING of Fat Loss Peptides
High-view (600K+ views) YouTube explainer using strong outcome language about retatrutide for fat loss. Tracked as a media signal for high-attention claims.
Retatrutide Masterclass (the 'how to' for EVERYTHING) - Dr Trevor Bachmeyer
Long-form YouTube masterclass format discussing retatrutide. Tracked as a discovery source for recurring public questions and claim patterns.